Smith & Nephew plc (LSE:SN.) is one of the FTSE 100's few genuine medical technology names, yet it sits near the bottom of its 52-week range while the FTSE 100 trades above 10,700. The shares changed hands at around 1,050p to 1,080p on 2 September 2026, close to the 1,046p low set on 21 August and far below the 1,441.5p high of September 2025, according to lse.co.uk.
The reason is not hard to find. On 4 August 2026 the group cut full-year Revenue growth guidance to around 4% from around 6%, and a fortnight later said chief financial officer John Rogers would leave at the end of September. The question is whether the profit resilience built under the 12-Point Plan and new RISE strategy can outlast a soft patch in Orthopaedics and wound bioactives.
Half-year results: revenue guidance cut, profit guidance held, and then the CFO walks
The half-year report for the 26 weeks to 27 June 2026, published on 4 August 2026, was a mixed message. Revenue rose 4.6% on a reported basis to $3,097m but only 2.3% underlying, with second-quarter underlying growth of just 1.6%. Management conceded that Orthopaedics and the SANTYL wound product had underperformed and cut full-year underlying revenue growth guidance to around 4%, having guided to around 6% at the 2 March 2026 full-year results.
Profit told a better story. Trading profit climbed 8.1% to $566m, lifting the trading Margin 60 basis points to 18.3%, and guidance for around 8% trading profit growth excluding acquisitions (around $1.3bn including Integrity Orthopaedics), free Cash Flow of around $800m and adjusted return on invested Capital above 10% was maintained.
Chief executive Deepak Nath said the 12-Point Plan had made the group "more resilient and better able to respond to such challenges", adding: "Orthopaedics is not where we want it to be, but we expect growth to accelerate as we Fill portfolio gaps, starting later this year and continuing into 2027."
Then, on 19 August 2026, the company announced that Mr Rogers would resign as CFO from 30 September 2026 to take a role in the United States, leaving the board immediately. Pierre Palassian, senior vice president finance and group controller since joining in 2017, becomes interim CFO while a successor is sought.
What Smith & Nephew does
Smith & Nephew sells medical devices across three franchises. Orthopaedics, the largest, supplies hip and knee implants, trauma products and the CORI handheld robotic surgery platform. Sports Medicine & ENT sells arthroscopic instruments, soft-tissue repair products such as REGENETEN and Q-FIX, the CARTIHEAL AGILI-C cartilage implant and, since January 2026, Integrity Orthopaedics' Tendon Seam rotator cuff system. Advanced Wound Management covers ALLEVYN dressings, the PICO negative pressure system, LEAF patient monitoring and bioactives including SANTYL and skin substitutes.
In the first half of 2026 the US contributed $1,591m of revenue, other established markets $958m and emerging markets $548m. The group reports in US dollars and has American Depositary Shares listed in New York alongside its London Stock Exchange main market listing.
Financial performance: margins expand while the Top Line stalls
For the half year to 27 June 2026, operating profit rose 4.3% to $448m and profit before tax 5.0% to $380m. Basic Earnings Per Share were 35.6¢, up 6.2%; adjusted earnings per share rose 11.0% to 47.7¢. Free cash flow slipped 5.2% to $231m as spending on a new UK wound-care factory, due to open in 2027, weighed on cash conversion. Net Debt including leases was $3,019m, up from $2,759m at 31 December 2025, with Leverage at 1.8 times adjusted EBITDA.
Segments diverged sharply. Sports Medicine & ENT grew underlying revenue 7.7% to $1,017m at a 24.7% trading margin, up 160 basis points. Advanced Wound Management was flat underlying at $867m with a 22.0% margin, as US reimbursement changes for skin substitutes created a headwind now expected at the upper end of the $20m to $40m range. Orthopaedics was also flat underlying at $1,213m, held back by a 7.2% fall in US knee implants and a 1.5% decline in US hips, although its trading margin improved 30 basis points to 13.0%.
The 12-Point Plan delivered $130m of savings in the half, with $200m targeted for 2026. The Interim Dividend rose 4.0% to 15.6¢ per share, and $216m of the $500m buyback announced on 6 May 2026 had been settled by 3 August. Full-year 2025 revenue was $6,164m with trading profit of $1,211m at a 19.7% margin.
What could drive the stock next?
The immediate catalyst is the third-quarter trading report on 6 November 2026, which will show whether the promised second-half step-up is materialising; revised guidance implies reported second-half revenue growth of 5.1% to 5.6%. Management has pointed to new Orthopaedics launches from late 2026 into 2027.
Innovation news flow is steady: the TESSA Spatial Surgery System received FDA De Novo classification for ACL reconstruction and CORI XT robotics completed its first cases. Integrity Orthopaedics, bought for $225m upfront plus up to $225m contingent, is expected to be accretive from 2028. Emerging markets grew 10.6% underlying, with China in double digits ahead of a volume-based procurement round delayed to the second half. A permanent CFO appointment and progress towards the RISE targets of 6% to 7% underlying revenue growth and 9% to 10% trading profit growth to 2028 will also be watched.
Risks investors should watch
The most obvious risk is that the revenue slowdown proves structural. US knee implants have been losing ground ahead of new products, and any launch delay would extend the drag. Skin-substitute reimbursement changes are already eroding bioactives growth, and SANTYL must return to growth in the third quarter as promised.
Leadership continuity is a fresh concern, with the CFO's exit coming two weeks after a guidance cut. Cash conversion has fallen sharply and net debt of just over $3bn is rising as the group funds acquisitions and buybacks. China's volume-based procurement remains a pricing threat, Tariff policy could shift again despite a currently neutral impact, and sterling investors carry dollar currency risk.
Outlook
Smith & Nephew (LSE:SN.) enters the autumn with profit guidance intact, an improving margin trajectory and a share price close to a 52-week low. What the market has not yet seen is evidence that Orthopaedics launches and a SANTYL recovery can restore top-line momentum.
The 6 November trading report is therefore the key test. Watch second-half revenue growth against the 5.1% to 5.6% range, the Orthopaedics margin, cash conversion, buyback progress and the timing of a permanent CFO appointment. Delivery would go a long way towards validating the RISE targets; a further miss would raise harder questions about the 2028 ambitions.






Please wait processing your request...